Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept in NPDR (PANORAMA)
NCT02718326Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 3 trial of aflibercept, sponsored by Regeneron Pharmaceuticals. Started Mar 2016; status: completed.
02
Drugs
aflibercept
Beyond the preview
Go deeper on NCT02718326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718326.